Should You Buy Eli Lilly and Company Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Eli Lilly and Company (LLY) ranks in the top tier of our coverage universe with a Quality of Company score of 9.8/10. Trading at a market price of $1,179.09, this high-quality profile requires careful comparison against our 13 intrinsic value models.
The short answer: 0 of 13 CirclFi valuation models project upside for Eli Lilly and Company (LLY) at $1179.09 — the model consensus leans bearish, with a Quality Score of 9.8/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Currently, no active models project meaningful upside for LLY at $1179.09. Bulls might argue that qualitative factors not captured by quantitative models could unlock value not reflected in current estimates.
The Bear Case
Target: $25.67 (-97.8%)
- According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $25.67 (-97.8%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +96.2% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
- Industry headwind: generic/biosimilar competition represents a meaningful risk for Eli Lilly and Company and its Drug Manufacturers - General peers.
The Bottom Line
Our valuation engine sends a clear cautionary signal on Eli Lilly and Company at $1,179.09. 12/13 models flag overvaluation, composite fair value sits at $320.14 (-72.8%), and the risk-reward profile appears unfavorable. Quality at 9.8/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Eli Lilly and Company's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy LLY stock right now?
Based on CirclFi's multi-model analysis, 0 of 13 models see upside for LLY at $1179.09. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Eli Lilly and Company?
Key risks include: wide model disagreement (4419% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - General companies. Always diversify and consult a financial advisor.
How does LLY compare to its competitors?
Among Drug Manufacturers - General peers, LLY holds a Quality Score of 9.8/10. Comparable companies include AZN (QOC 10.0), NVO (QOC 10.0), GILD (QOC 9.7). The relative ranking helps investors identify whether LLY offers better fundamental quality than alternatives in the same sector.
Is LLY a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. LLY's Quality Score of 9.8/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy LLY at?
CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $25.67 to $1160.24. At $1179.09, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for LLY.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad